176 related articles for article (PubMed ID: 11493174)
1. Measurement of antibodies to interferon beta in patients with multiple sclerosis.
Pachner AR
Arch Neurol; 2001 Aug; 58(8):1299-300. PubMed ID: 11493174
[No Abstract] [Full Text] [Related]
2. Commentary on neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Whitaker JN
Arch Neurol; 2001 Aug; 58(8):1301. PubMed ID: 11493175
[No Abstract] [Full Text] [Related]
3. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist.
Pachner AR
Neurology; 1997 Sep; 49(3):647-50. PubMed ID: 9305316
[No Abstract] [Full Text] [Related]
4. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice G
Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
[No Abstract] [Full Text] [Related]
5. Long-term evolution of anti-INFbeta antibodies in IFNbeta-treated MS patients: the London, Canada, MS Clinic experience.
Kremenchutzky M
Neurology; 2003 Nov; 61(9 Suppl 5):S29-30. PubMed ID: 14610109
[No Abstract] [Full Text] [Related]
6. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
[TBL] [Abstract][Full Text] [Related]
7. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
8. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
Rice GP; Paszner B; Oger J; Lesaux J; Paty D; Ebers G
Neurology; 1999 Apr; 52(6):1277-9. PubMed ID: 10214759
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta.
Mayorga C; Luque G; Romero F; Guerrero R; Blanca M; Fernandez O
Int Arch Allergy Immunol; 1999; 118(2-4):368-71. PubMed ID: 10224450
[No Abstract] [Full Text] [Related]
10. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau J; White R
Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
[No Abstract] [Full Text] [Related]
11. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
12. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
13. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.
Gilli F; Hoffmann F; Sala A; Marnetto F; Caldano M; Valentino P; Kappos L; Bertolotto A; Lindberg RL
Mult Scler; 2006 Dec; 12(6):738-46. PubMed ID: 17263001
[TBL] [Abstract][Full Text] [Related]
14. [Beta-interferon neutralizing antibodies. Do they have clinical value in patients with multiple sclerosis?].
Romero López J; Maciñeiras Montero JL
Med Clin (Barc); 2005 Feb; 124(4):144-5. PubMed ID: 15713245
[No Abstract] [Full Text] [Related]
15. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
[TBL] [Abstract][Full Text] [Related]
16. Neutralising antibodies to interferon beta.
Ortenzi C
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1162; author reply 1162-3. PubMed ID: 12876267
[No Abstract] [Full Text] [Related]
17. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients.
Pachner AR
Neurology; 2003 Nov; 61(10):1444-6. PubMed ID: 14638976
[TBL] [Abstract][Full Text] [Related]
18. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
[TBL] [Abstract][Full Text] [Related]
19. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
Kracke A; von Wussow P; Al-Masri AN; Dalley G; Windhagen A; Heidenreich F
Neurology; 2000 Jan; 54(1):193-9. PubMed ID: 10636147
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]